A Phase III clinical trials worldwide for the U.S.
A new website was launched to facilitate the recruitment of patients to OVATURE (ovarian response), a Phase III clinical trial of an investigational drug phenoxodiol ovarian cancer. The aim is to inform OVATURE OVATUREtrial in patients with ovarian cancer test, which is recruiting patients and to provide more information on the process and phenoxodiol drug.participating physicians. Hospitals and treatment centers in the United States, Europe and Australia serve as test sites, and patients OVATUREtrial leading positions at the site, and beginning to recruit. Patients with ovarian cancer initially responded to chemotherapy, but has become resistant or refractory to conventional platinum are eligible to participate. United States
Womens Cancer Center of Nevada, Las
Vegas, Nevada, the University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, Providence Hospital and Medical Center in Southfield, Michigan, Hematology Oncology in Stamford, Connecticut; Gabrail Cancer Center in Canton, Ohio, Northern Virginia Pelvic Surgery Associates in Annandale, Va., and Chattanooga GYN Oncology in Chattanooga, Tennessee.Adelaide, Brisbane Mater Adult Hospital. In Europe, 26 sites are planned and recruitment began in Gynecologic Oncology, UZ Leuven in Leuven, Belgium. The study examined the safety and efficacy of phenoxodiol drugs not yet approved for public distribution by the FDA when used in combination with weekly doses of chemotherapy drugs, carboplatin. The test consists of two arms of double-blind treatment. Patients in the study
group received carboplatin and weekly phenoxodiol.Patients in the study arm will receive weekly carboplatin other, but a placebo will be substituted for Phenoxodiol. Neither the patients nor the doctors know which arm of the study patients will be randomized. A change of carboplatin (or cisplatin) every two received three weeks ago on a diet weekly carboplatin was reported to provide a tumor response in some patients
Pages: [1] 2 3 4